Prediction of Cancer Incidence and Mortality in Korea, 2013

Kyu-Won Jung; Young-Joo Won; Hyun-Joo Kong; Chang-Mo Oh; Hong Gwan Seo; Jin-Soo Lee

doi:10.4143/crt.2013.45.1.15

Articles

Page Path: HOME > Cancer Res Treat > Volume 45(1); 2013 > Article

Special Article Prediction of Cancer Incidence and Mortality in Korea, 2013: Kyu-Won Jung, MS¹, Young-Joo Won, PhD¹, Hyun-Joo Kong, MS¹, Chang-Mo Oh, MD¹, Hong Gwan Seo, MD, PhD², Jin-Soo Lee, MD, PhD¹; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2013;45(1):15-21.
DOI: https://doi.org/10.4143/crt.2013.45.1.15
Published online: March 31, 2013

¹The Korea Central Cancer Registry, Division of Cancer Registration and Surveillance, National Cancer Center, Goyang, Korea.

²National Cancer Control Institute, National Cancer Center, Goyang, Korea.

Correspondence: Young-Joo Won, PhD. The Korea Central Cancer Registry, Division of Cancer Registration and Surveillance, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 410-769, Korea.
Tel: 82-31-920-2015, Fax: 82-31-920-2179, astra67@ncc.re.kr

• Received: February 26, 2013 • Accepted: February 27, 2013

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

18,320 Views
97 Download
54 Crossref
58 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
To estimate the current cancer burden in Korea, cancer incidence and mortality rates were projected for the year 2013.
Materials and Methods
Cancer incidence data from 1999 to 2010 were obtained from the Korea National Cancer Incidence Database, and cancer mortality data from 1993 to 2011 were obtained from Statistics Korea. Cancer incidence in 2013 was projected by fitting a linear regression model to observed age-specific cancer incidence rates against observed years, then multiplying the projected age-specific rates by the age-specific population. For cancer mortality, a similar procedure was used, except that a Joinpoint regression model was used to determine at which year the linear trend changed significantly.
Results
In total, 247,732 new cancer cases and 74,179 cancer deaths are projected to occur in Korea in 2013. For all sites combined, the crude incidence rates are projected to be 489.8 and 492.2, and the age-standardized incidences to be 350.4 and 318.4 per 100,000 for males and females, respectively.
Conclusion
Cancer has become an important public health concern in Korea, and as the Korean population ages, the cancer burden will continue to increase.
Key words: Incidence, Mortality, Neoplasms, Forecasting, Korea, 2013

Introduction

Since 1983, as the leading cause of death [1], cancer has become a major public health concern in Korea. Annually, over 200,000 patients are newly diagnosed with cancer in Korea, and one in four deaths is due to cancer [2,3]. Although the cancer registration system in Korea is very efficient and can provide nationwide cancer statistics within a relatively short time, an at least 2-year lag for accurate data collection and compilation is necessary. To plan and apply a cancer control program, it is important to assess the number of new cases and deaths that are expected to occur during the current year. In this report, we provide the projected cancer incidence and mortality rate based on data up to 2010.

Materials and Methods

The Korean Ministry of Health and Welfare initiated a nationwide, hospital-based cancer registry (the Korea Central Cancer Registry [KCCR]) in 1980. The details of the history, objectives, and activities of the KCCR have been documented elsewhere [4]. Incidence data from 1999 to 2010 were obtained from the Korea National Cancer Incidence Database (KNCI DB). Cancer cases were classified according to the International Classification of Diseases for Oncology, 3rd edition [5] and converted according to the International Classification of Diseases, 10th edition (ICD-10) [6].

Mortality data from 1993 to 2011 were obtained from Statistics Korea [1]. The cause of death was coded and classified according to ICD-10.

The cancer sites included in this report are 1) all cancers combined and 2) the 24 most common cancers: lip, oral cavity, and pharynx (C00-C14), esophagus (C15), stomach (C16), colon and rectum (C18-C20), liver and intrahepatic bile duct (liver) (C22), gallbladder and other parts of the biliary tract (gallbladder) (C23-C24), pancreas (C25), larynx (C32), lung and bronchus (lung) (C33-C34), breast (C50), cervix uteri (C53), corpus uteri (C54), ovary (C56), prostate (C61), testis (C62), kidney (C64), bladder (C67), brain and central nervous system (C70-C72), thyroid (C73), Hodgkin lymphoma (C81), non-Hodgkin lymphoma (C82-C85, C96), multiple myeloma (C90), leukemia (C91-C95), and all others.

Population data were obtained from the resident registration population, reported by Statistics Korea. The mid-year population, on July 1 of the respective year, was used when computing the incidence and deaths.

Due to the time required for data collection and analysis, incidence and mortality data are available usually 2-3 years behind the current year. Thus, we projected the expected number of new cancer cases and deaths in Korea in the current year to provide an estimate of the current cancer burden.

Linear regression models [7] were used to assess time trends and the projection of rates. Based on the observed cancer incidence data, a linear regression model was fitted to the age-specific rates by 5-year age group against observed years. From the projected age-specific rates in 2013, the estimated number of cancer cases was calculated by multiplying the rates by the projected 2013 age-specific population size. For thyroid and prostate cancer, which showed significant curvilinear trends, we used a square-root transformation when fitting a linear regression model and converted the predicted values back to the original scale.

To estimate the number of cancer deaths in 2013, we first ran a Joinpoint regression model on the data for 1993-2011 to detect the year of significant changes in the trends in cancer mortality by sex and cancer site. A Joinpoint regression describes changes in data trends by connecting several different line segments on a log scale at "joinpoints." This analysis was performed using the Joinpoint software (ver. 4.0; http://surveillance.cancer.gov/joinpoint) from the Surveillance Research Program of the US National Cancer Institute [8]. After identifying the year of significant trend changes using Joinpoint regression analysis, a simple linear regression model was fitted to the last line segment to estimate age-specific cancer mortality rates in 2013. Similar to the method used for the projection of cancer incidence, the number of new deaths was then projected by multiplying the age-specific cancer mortality rates by 2013's projected age-specific population.

We summarized the results using crude rates (CRs) and age-standardized rates (ASRs) of cancer incidence and mortality. The ASRs were standardized using the world standard population [9].

Results

1. Incidence

Table 1 presents the estimated number of new cancer cases and deaths during 2013 in Korea by sex and cancer site. It is projected that 247,732 cancer incidence cases will occur in 2013.

Table 2 presents the estimated CRs and ASRs of cancer incidence in 2013 by sex and cancer site. The CRs of all sites combined in males and females in 2013 are projected to be 489.8 and 492.2, respectively, per 100,000, and the ASRs of all sites combined are projected to be 350.4 and 318.4, respectively, per 100,000. In males, the five leading primary sites of cancer are expected to be the stomach (CR, 89.1; ASR, 62.6), colon and rectum (CR, 82.2; ASR, 58.1), lung (CR, 65.3; ASR, 46.1), liver (CR, 49.4; ASR, 34.4), and prostate (CR, 48.3; ASR, 34.5), accounting for 68.2% of all newly diagnosed cancers in 2013. In females, the five leading primary sites are expected to be thyroid (CR, 174.4; ASR, 124.1), breast (CR, 67.6; ASR, 45.8), colon and rectum (CR, 51.7; ASR, 29.8), stomach (CR, 42.1; ASR, 24.6), and lung (CR, 28.0; ASR, 15.0), accounting for 73.9% of all newly diagnosed cancers (Fig. 1). Thyroid cancer alone is projected to account for 35.4% (43,973 cases) of incident cases in females in 2013.

Table 3 presents the most common cancer sites expected in 2013 by sex and age group. Leukemia and thyroid cancer are projected to be the most common forms of cancer in both sexes for the 0-14 and 15-34 age groups. Gastric cancer is predicted to be the most common cancer in males 35-64 years of age, while lung cancer is predicted to be more frequent in males≥65 years of age. Thyroid cancer is predicted to be the most common cancer in females 35-64 years of age, whereas colorectal cancer is predicted to be the most common cancer in females≥65 years of age. Fig. 2 shows the age-specific incidence rates of the selected cancers for males and females in 2013. The projection indicates that the incidences of gastric, lung, liver, and colorectal cancers will increase gradually with age. In women, the age-specific incidence rates of breast and thyroid cancer will increase with age until 50 years of age, and then level off.

2. Mortality

It is estimated that 74,179 cancer deaths will occur in Korea during 2013 (Table 1, Fig. 2). The CRs of all sites combined in 2013 for males and females are projected to be 184.7 and 109.3, respectively, per 100,000, and the ASRs of all sites combined are expected to be 131.8 and 56.3, respectively, per 100,000 (Table 4).

In 2013, the five leading cancer sites causing mortality in males are predicted to be lung (CR, 47.4; ASR, 33.4), liver (CR, 31.7; ASR, 22.3), colon and rectum (CR, 22.3; ASR 16.0), stomach (CR, 21.2; ASR, 15.1), and pancreas (CR, 10.8; ASR, 7.7). During the same time period, in females, lung cancer (CR, 17.8; ASR, 8.6) is projected to be the leading cancer site causing mortality, followed by cancers of the colon and rectum (CR, 14.3; ASR, 7.0), stomach (CR, 11.7; ASR, 5.7), liver (CR, 10.8; ASR, 5.6), and pancreas (CR, 9.1; ASR, 4.5).

Fig. 3 shows the age-specific predicted mortality rates of the selected cancers for males and females in 2013. When examined by age, Korean males≥60 years of age are expected to have the highest mortality rates from lung cancer. In contrast, Korean females≥55 years of age are expected to have the highest mortality rates from breast cancer, followed by lung cancer.

Conclusion

This report provides estimated nationwide cancer incidence and mortality in Korea for the current year. In total, 247,732 new cancer cases and 74,179 cancer deaths are expected in Korea during 2013. In Korean males, gastric, colorectal, lung, liver, and prostate cancers are estimated to have the highest incidences, while lung, liver, colorectal, gastric, and pancreatic cancers are estimated to be the most common causes of cancer-related deaths. In Korean females, thyroid, breast, colorectal, gastric, and lung cancer are estimated to have the highest incidences, while lung, colorectal, gastric, liver, and pancreatic cancers are estimated to be the most common causes of cancer-related deaths.

Cancer has become an important public health concern in Korea, and as the population continues to age, the cancer burden will continue to increase. The estimated cancer statistics for the current year given in this report represent an important resource for planning and evaluating cancer-control programs. The estimates in this report, however, are projected numbers based on statistical models and may vary from year to year; hence, these estimates should be used with caution.

Acknowledgements

Acknowledgments

This work was supported by a research grant from the National Cancer Center (No. 1310220), Republic of Korea.

NOTES

Conflict of interest relevant to this article was not reported.

REFERENCES

1. Statistics Korea [Internet]. 2013. cited 2013 Jan 4Daejeon: Statistics Korea; Available from: http://kostat.go.kr
2. Ministry of Health and Welfare2010 Annual report of cancer statistics in Korea. 2012. Seoul: Ministry of Health and Welfare.
3. Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Seo HG, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat. 2012;44:11–24. PMID: 22500156Article PubMed PMC PDF
4. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat. 2005;37:325–331. PMID: 19956367Article PubMed PMC PDF
5. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. 2000. 3rd ed. Geneva: World Health Organization.
6. World Health OrganiztionInternational statistical calssification of diseases and related health problems. 1994. 10th rev. Geneva: World Health Organization.
7. Boyle P, Parkin DM. . In: Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG, editors. Statistical methods for registries. Cancer registration: principles and methods. No. 95. 1991. Lyon: IARC; p. 126–158.
8. National Cancer InstituteJoinpoint regression program, version 4.0 [Internet]. 2013. cited 2013 Jan 4Bethesda, MD: National Cancer Institute; Available from: http://surveillance.cancer.gov/joinpoint/
9. Segi M. Cancer mortality for selected sites in 24 countries (1950-1957). 1960. Sendai: Tohoku University School of Medicine.

Fig. 1

The 10 leading types of estimated new cancer cases and deaths by sex in 2013. (A) Estimated new cases. (B) Estimated deaths.

Fig. 2

Projected age-specific incidences of major cancers during 2013 in Korea. (A) Male. (B) Female.

Fig. 3

Projected age-specific mortality rates of major cancers during 2013 in Korea. (A) Male. (B) Female.

Table 1

Estimated new cancer cases and deaths by sex during 2013 in Korea

Site	Estimated new cases			Estimated deaths
Site	Both	Male	Female	Both	Male	Female
All sites	247,732	123,610	124,122	74,179	46,610	27,569
Lip, oral cavity, and pharynx	2,897	2,142	755	1,007	739	268
Esophagus	2,273	2,089	184	1,242	1,158	84
Stomach	33,118	22,495	10,623	8,292	5,346	2,946
Colon and rectum	33,789	20,745	13,044	9,221	5,620	3,601
Liver	16,845	12,456	4,389	10,734	8,005	2,729
Gallbladder^a)	5,637	2,823	2,814	3,918	1,893	2,025
Pancreas	5,581	2,986	2,595	5,037	2,732	2,305
Larynx	1,072	1,032	40	211	200	11
Lung	23,543	16,479	7,064	16,448	11,963	4,485
Breast	17,104	67	17,037	2,207	18	2,189
Cervix uteri	3,240	-	3,240	825	-	825
Corpus uteri	2,174	-	2,174	262	-	262
Ovary	2,199	-	2,199	1,003	-	1,003
Prostate	12,180	12,180	-	1,620	1,620	-
Testis	221	221	-	19	19	-
Kidney	4,549	3,139	1,410	894	596	298
Bladder	4,043	3,255	788	1,087	780	307
Brain and CNS	1,872	999	873	1,112	608	504
Thyroid	52,485	8,512	43,973	372	104	268
Hodgkin lymphoma	267	173	94	52	30	22
Non-Hodgkin lymphoma	4,684	2,580	2,104	1,521	876	645
Multiple myeloma	1,312	689	623	965	515	450
Leukemia	2,936	1,657	1,279	1,690	977	713
Other and ill defined	13,711	6,891	6,820	4,440	2,811	1,629

CNS, central nervous system. ^a)Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 2

Estimated crude and age-standardized cancer incidences by sex during 2013 in Korea

Site	Crude incidence rate per 100,000			Age-standardized incidence rate per 100,000^a)
Site	Both	Male	Female	Both	Male	Female
All sites	491.0	489.8	492.2	324.2	350.4	318.4
Lip, oral cavity, and pharynx	5.7	8.5	3.0	3.9	6.0	2.0
Esophagus	4.5	8.3	0.7	2.8	5.9	0.4
Stomach	65.6	89.1	42.1	41.9	62.6	24.6
Colon and rectum	67.0	82.2	51.7	42.7	58.1	29.8
Liver	33.4	49.4	17.4	21.4	34.4	9.8
Gallbladder^b)	11.2	11.2	11.2	6.7	8.0	5.6
Pancreas	11.1	11.8	10.3	6.7	8.4	5.3
Larynx	2.1	4.1	0.2	1.3	2.9	0.1
Lung	46.7	65.3	28.0	28.2	46.1	15.0
Breast	33.9	0.3	67.6	23.1	0.2	45.8
Cervix uteri	6.4	-	12.9	4.3	-	8.4
Corpus uteri	4.3	-	8.6	2.9	-	5.7
Ovary	4.4	-	8.7	3.0	-	6.0
Prostate	24.1	48.3	-	15.0	34.5	-
Testis	0.4	0.9	-	0.5	0.9	-
Kidney	9.0	12.4	5.6	6.1	8.9	3.6
Bladder	8.0	12.9	3.1	4.8	9.1	1.6
Brain and CNS	3.7	4.0	3.5	3.1	3.5	2.7
Thyroid	104.0	33.7	174.4	73.7	24.0	124.1
Hodgkin lymphoma	0.5	0.7	0.4	0.5	0.6	0.3
Non-Hodgkin lymphoma	9.3	10.2	8.3	6.6	7.8	5.6
Multiple myeloma	2.6	2.7	2.5	1.6	1.9	1.4
Leukemia	5.8	6.6	5.1	5.2	6.1	4.4
Other and ill defined	27.2	27.3	27.0	18.3	20.7	16.4

CNS, central nervous system. ^a)Age adjusted to the world standard population, ^b)Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 3

Estimated cancer incidence by age group and sex during 2013 in Korea

Rank	Age group (yr)
Rank	0-14	15-34	35-64	≥65
Male
1	Leukemia	Thyroid	Stomach	Lung
	(5.1)	(14.6)	(99.9)	(478.9)
2	Brain and CNS	Leukemia	Colon and rectum	Stomach
	(2.6)	(3.3)	(90.9)	(445.5)
3	Non-Hodgkin lymphoma	Colon and rectum	Liver	Colon and rectum
	(2.0)	(3.0)	(64.5)	(414.0)
4	Kidney	Non-Hodgkin lymphoma	Thyroid	Prostate
	(0.6)	(3.0)	(57.4)	(374.0)
5	Testis	Stomach	Lung	Liver
	(0.4)	(2.3)	(41.7)	(202.9)
Female
1	Leukemia	Thyroid	Thyroid	Colon and rectum
	(4.0)	(79.3)	(307.8)	(204.9)
2	Brain and CNS	Breast	Breast	Stomach
	(2.0)	(11.4)	(123.8)	(157.0)
3	Non-Hodgkin lymphoma	Cervix uteri	Colon and rectum	Lung
	(1.0)	(5.2)	(50.8)	(131.4)
4	Ovary	Stomach	Stomach	Thyroid
	(0.8)	(4.2)	(43.2)	(108.0)
5	Thyroid	Ovary	Lung	Liver
	(0.6)	(2.8)	(21.7)	(78.2)

CNS, central nervous system.

Table 4

Estimated crude and age-standardized cancer mortality rates by sex during 2013 in Korea

Site	Crude mortality rate per 100,000			Age-standardized mortality rate per 100,000^a)
Site	Both	Male	Female	Both	Male	Female
All sites	147.0	184.7	109.3	87.7	131.8	56.3
Lip, oral cavity, and pharynx	2.0	2.9	1.1	1.2	2.0	0.6
Esophagus	2.5	4.6	0.3	1.5	3.2	0.1
Stomach	16.4	21.2	11.7	9.6	15.1	5.7
Colon and rectum	18.3	22.3	14.3	10.7	16.0	7.0
Liver	21.3	31.7	10.8	13.3	22.3	5.6
Gallbladder^b)	7.8	7.5	8.0	4.4	5.4	3.7
Pancreas	10.0	10.8	9.1	5.9	7.7	4.5
Larynx	0.4	0.8	0.0	0.2	0.6	0.0
Lung	32.6	47.4	17.8	18.9	33.4	8.6
Breast	4.4	0.1	8.7	2.9	0.1	5.5
Cervix uteri	1.6	-	3.3	1.0	-	1.8
Corpus uteri	0.5	-	1.0	0.3	-	0.6
Ovary	2.0	-	4.0	1.2	-	2.3
Prostate	3.2	6.4	-	1.7	4.8	-
Testis	0.0	0.1	-	0.0	0.1	-
Kidney	1.8	2.4	1.2	1.1	1.7	0.6
Bladder	2.2	3.1	1.2	1.2	2.3	0.5
Brain and CNS	2.2	2.4	2.0	1.6	1.9	1.3
Thyroid	0.7	0.4	1.1	0.4	0.3	0.5
Hodgkin lymphoma	0.1	0.1	0.1	0.1	0.1	0.1
Non-Hodgkin lymphoma	3.0	3.5	2.6	1.8	2.5	1.3
Multiple myeloma	1.9	2.0	1.8	1.2	1.4	1.0
Leukemia	3.4	3.9	2.8	2.3	3.0	1.8
Other and ill defined	8.8	11.1	6.5	5.3	8.1	3.3

CNS, central nervous system. ^a)Age adjusted to the world standard population, ^b)Includes the gallbladder and other/unspecified parts of the biliary tract.

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Personalizing perioperative therapy in muscle-invasive bladder cancer: balancing oncologic benefit, toxicity, and the risk of overtreatment
Geehyun Song, Whi-An Kwon, Eui Hyun Jung, Dai Hong Phuc Vo, Ho Trong Tan Truong, Ho Kyung Seo
Journal of the Korean Medical Association.2025; 68(4): 215. CrossRef
Evaluation and forecasting methods to estimate number of patients with non-Hodgkin lymphoma: a systematic literature review
Dan Lin, Changxia Shao, James R. Rogers, Mehmet Burcu, Helmneh M. Sineshaw
Population Health Metrics.2025;[Epub] CrossRef
RETRACTED: Impact of robotic and open surgery on patient wound complications in gastric cancer surgery: A meta‐analysis
Lu Ye, Qian Yang, Yuyu Xue, Rong Jia, Li Yang, Lili Zhong, Liqun Zou, Yao Xie
International Wound Journal.2023; 20(10): 4262. CrossRef
The Global Burden of Leukemia and Its Attributable Factors in 204 Countries and Territories: Findings from the Global Burden of Disease 2019 Study and Projections to 2030
Mengbao Du, Weiwei Chen, Ke Liu, Limengmeng Wang, Yihan Hu, Yingying Mao, Xiaohui Sun, Yi Luo, Jimin Shi, Keding Shao, He Huang, Ding Ye, Irena Ilic
Journal of Oncology.2022; 2022: 1. CrossRef
Usefulness of computed tomography venography in gynecologic cancer patients with lower extremity edema
Won Jun Kim, JaYoung Kim, Minsoo Kang, Dae Hwan Park, Jae Yong Jeon
Medicine.2020; 99(37): e21818. CrossRef
Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708)
Young Shin Chung, Sang-Yoon Park, Jung-Yun Lee, Jeong-Yeol Park, Jeong-Won Lee, Hee Seung Kim, Dong Soo Suh, Yun Hwan Kim, Jong-Min Lee, Miseon Kim, Min Chul Choi, Seung-Hyuk Shim, Keun Ho Lee, Taejong Song, Jin Hwa Hong, Won Moo Lee, Banghyun Lee, In Ho
BMC Cancer.2019;[Epub] CrossRef
National practice patterns and direct medical costs for prostate cancer in Korea across a 10 year period: a nationwide population-based study using a national health insurance database
Ho Won Kang, Seok-Joong Yun, Jae Il Chung, Hoon Choi, Jae Heon Kim, Ho Song Yu, Yun-Sok Ha, In-Chang Cho, Hyung Joon Kim, Hyun Chul Chung, Jun Sung Koh, Wun-Jae Kim, Jong-Hyock Park, Ji Youl Lee, So-Young Kim
BMC Health Services Research.2019;[Epub] CrossRef
Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience
Young Shin Chung, Jung-Yun Lee, Hyun-Soo Kim, Eun Ji Nam, Sang Wun Kim, Young Tae Kim
Yonsei Medical Journal.2018; 59(8): 930. CrossRef
Towards Prevention of Breast Cancer: What Are the Clinical Challenges?
Signe Borgquist, Per Hall, Isaac Lipkus, Judy E. Garber
Cancer Prevention Research.2018; 11(5): 255. CrossRef
Additive treatment improves survival in elderly patients after non-curative endoscopic resection for early gastric cancer
Da Hyun Jung, Yong Chan Lee, Jie-Hyun Kim, Sang Kil Lee, Sung Kwan Shin, Jun Chul Park, Hyunsoo Chung, Jae Jun Park, Young Hoon Youn, Hyojin Park
Surgical Endoscopy.2017; 31(3): 1376. CrossRef
Adjuvant Chemotherapy for Advanced Gastric Cancer in Elderly and Non-elderly Patients: Meta-Analysis of Randomized Controlled Trials
Seong-Hwan Chang, Soo-Nyung Kim, Hye Jung Choi, Misuk Park, Rock Bum Kim, Se-Il Go, Won Sup Lee
Cancer Research and Treatment.2017; 49(1): 263. CrossRef
Analysis of the Clinicopathological Characteristics of Gastric Cancer in Extremely Old Patients
Il Woong Sohn, Da Hyun Jung, Jie-Hyun Kim, Hyun Soo Chung, Jun Chul Park, Sung Kwan Shin, Sang Kil Lee, Yong Chan Lee
Cancer Research and Treatment.2017; 49(1): 204. CrossRef
Fecal occult blood test/fecal carcinoembriogenic antigen dual rapid test as a useful tool for colorectal cancer screening
Maru Kim, Hyung-Jin Kim, In Kyu Lee, Seong-Taek Oh, Kyungja Han
European Surgery.2017; 49(3): 127. CrossRef
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea
Seung Hoon Beom, Jisu Oh, Tae-Yong Kim, Kyung-Hun Lee, Yaewon Yang, Koung Jin Suh, Hyeong-Gon Moon, Sae-Won Han, Do-Youn Oh, Wonshik Han, Tae-You Kim, Dong-Young Noh, Seock-Ah Im
Cancer Research and Treatment.2017; 49(2): 454. CrossRef
HIPK2 Overexpression and Its Prognostic Role in Human Papillomavirus-Positive Tonsillar Squamous Cell Carcinoma
Mi Jung Kwon, So Young Kang, Eun Sook Nam, Seong Jin Cho, Young-Soo Rho
BioMed Research International.2017; 2017: 1. CrossRef
Extensive Lymph Node Dissection Improves Survival among American Patients with Gastric Adenocarcinoma Treated Surgically: Analysis of the National Cancer Database
Samer A. Naffouje, George I. Salti
Journal of Gastric Cancer.2017; 17(4): 319. CrossRef
Second Primary Cancer after Diagnosis and Treatment of Cervical Cancer
Myong Cheol Lim, Young-Joo Won, Jiwon Lim, Yeon-Joo Kim, Sang Soo Seo, Sokbom Kang, Eun Sook Lee, Jae Hwan Oh, Joo-Young Kim, Sang-Yoon Park
Cancer Research and Treatment.2016; 48(2): 641. CrossRef
Surgical management of advanced gastric cancer: An evolving issue
L. Marano, K. Polom, A. Patriti, G. Roviello, G. Falco, A. Stracqualursi, R. De Luca, R. Petrioli, M. Martinotti, D. Generali, D. Marrelli, N. Di Martino, F. Roviello
European Journal of Surgical Oncology (EJSO).2016; 42(1): 18. CrossRef
The Clinical Status of Radiation Therapy in Korea in 2009 and 2013
Jin-Kyu Kang, Mi-Sook Kim, Won-Il Jang, Hee Jin Kim, Chul Koo Cho, Hyung Jun Yoo, Young Seok Seo, Eun Kyung Paik, Yu Jin Cha
Cancer Research and Treatment.2016; 48(3): 892. CrossRef
Rosuvastatin Induces ROS-mediated Apoptosis in Human Prostate Cancer PC-3 Cells
Hyeun Deok Choi, Jong Jin Baik, Sang Hun Kim, Sun Nyoung Yu, Sung Hak Chun, Young Wook Kim, Hyo Won Nam, Kwang Youn Kim, Soon Cheol Ahn
Journal of Life Science.2016; 26(4): 398. CrossRef
Proteomic analysis of selective cytotoxic anticancer properties of flavonoids isolated from Citrus platymamma on A549 human lung cancer cells
Arulkumar Nagappan, Venu Venkatarame Gowda Saralamma, Gyeong Eun Hong, Ho Jeong Lee, Sung Chul Shin, Eun Hee Kim, Won Sup Lee, Gon Sup Kim
Molecular Medicine Reports.2016; 14(4): 3814. CrossRef
Advanced gastric cancer: What we know and what we still have to learn
Federico Coccolini
World Journal of Gastroenterology.2016; 22(3): 1139. CrossRef
Flavonoids isolated from Citrus platymamma induced G2/M cell cycle arrest and apoptosis in A549 human lung cancer cells
Arulkumar Nagappan, Ho Jeong Lee, Venu Venkatarame Gowda Saralamma, Hyeon Soo Park, Gyeong Eun Hong, Silvia Yumnam, Suchismita Raha, Shobana Nancy Charles, Sung Chul Shin, Eun Hee Kim, Won Sup Lee, Gon Sup Kim
Oncology Letters.2016; 12(2): 1394. CrossRef
Comparison of Therapeutic Efficacy and Clinical Parameters Between Recombinant Human Thyroid Stimulating Hormone and Thyroid Hormone Withdrawal in High-Dose Radioiodine Treatment with Differentiated Thyroid Cancer
Sehun Choi, Chang Ju Na, Jeonghun Kim, Yeon-Hee Han, Hee-Kwon Kim, Hwan-Jeong Jeong, Myung-Hee Sohn, Seok Tae Lim
Nuclear Medicine and Molecular Imaging.2015; 49(2): 115. CrossRef
Benefit of Negative-pressure Drain Within Surgical Wound After Cytoreductive Surgery for Ovarian Cancer
Se Ik Kim, Myong Cheol Lim, Hyo Sook Bae, Se Ra Shin, Sang-Soo Seo, Sokbom Kang, Sang-Yoon Park
International Journal of Gynecological Cancer.2015; 25(1): 145. CrossRef
Low Frequency of KRAS Mutation in Pancreatic Ductal Adenocarcinomas in Korean Patients and Its Prognostic Value
Mi Jung Kwon, Jang Yong Jeon, Hye-Rim Park, Eun Sook Nam, Seong Jin Cho, Hyung Sik Shin, Ji Hyun Kwon, Joo Seop Kim, Boram Han, Dong Hoon Kim, Yoon-La Choi
Pancreas.2015; 44(3): 484. CrossRef
Clinical significance of mismatch repair genes immunohistochemical expression of complex endometrial hyperplasia
Su Jin Han, Min Kyu Kim
Obstetrics & Gynecology Science.2015; 58(2): 106. CrossRef
Minimally invasive gastrectomy for cancer: current utilization in US academic medical centers
Jason A. Glenn, Kiran K. Turaga, T. Clark Gamblin, Samuel F. Hohmann, Fabian M. Johnston
Surgical Endoscopy.2015; 29(12): 3768. CrossRef
Anthocyanins From the Fruit of Vitis coignetiae Pulliat Potentiate the Cisplatin Activity by Inhibiting PI3K/Akt Signaling Pathways in Human Gastric Cancer Cells
Jing Nan Lu, Won Sup Lee, Arulkumar Nagappan, Seong-Hwan Chang, Yung Hyun Choi, Hye Jung Kim, Gon Sup Kim, Chung Ho Ryu, Sung Chul Shin, Jin-Myung Jung, Soon Chan Hong
Journal of Cancer Prevention.2015; 20(1): 50. CrossRef
Hepatocellular Carcinoma with Cervical Spine and Pelvic Bone Metastases Presenting as Unknown Primary Neoplasm
Seawon Hwang, Jieun Lee, Jung Min Lee, Sook Hee Hong, Myung-Ah Lee, Hoo Geun Chun, Ho Jong Chun, Sung Hak Lee, Eun Sun Jung
The Korean Journal of Gastroenterology.2015; 66(1): 50. CrossRef
Preventing breast cancer now by acting on what we already know
Graham A Colditz, Kari Bohlke
npj Breast Cancer.2015;[Epub] CrossRef
Association between information provision and decisional conflict in cancer patients
J.A. Sim, J.S. Shin, S.M. Park, Y.J. Chang, A. Shin, D.Y. Noh, W. Han, H.K. Yang, H.J. Lee, Y.W. Kim, Y.T. Kim, S.Y. Jeong, J.H. Yoon, Y.J. Kim, D.S. Heo, T.Y. Kim, D.Y. Oh, H.G. Wu, H.J. Kim, E.K. Chie, K.W. Kang, Y.H. Yun
Annals of Oncology.2015; 26(9): 1974. CrossRef
D-Dimer Can Serve as a Prognostic and Predictive Biomarker for Metastatic Gastric Cancer Treated by Chemotherapy
Se-Il Go, Min Jeong Lee, Won Sup Lee, Hye Jung Choi, Un Seok Lee, Rock Bum Kim, Myoung Hee Kang, Hoon-Gu Kim, Gyeong-Won Lee, Jung Hun Kang, Jeong-Hee Lee, Sun Joo Kim
Medicine.2015; 94(30): e951. CrossRef
A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1
Umasankar De, Soma Kundu, Nabanita Patra, Mee Young Ahn, Ji Hae Ahn, Ji Yeon Son, Jung Hyun Yoon, Hyung Ryoung Moon, Byung Mu Lee, Hyung Sik Kim
Biomolecules & Therapeutics.2015; 23(5): 434. CrossRef
Young Women with Breast Cancer in the United States and South Korea: Comparison of Demographics, Pathology and Management
Byung Ho Son, Laura S Dominici, Fatih Aydogan, Lawrence N Shulman, Sei Hyn Ahn, Ja Young Cho, Suzanne B Coopey, Sung Bae Kim, H Elise Min, Monica Valero, Jiping Wang, Diana Caragacianu, Gyung-yub Gong, Nathanael D Hevelone, Seunghee Baek, Mehra Golshan
Asian Pacific Journal of Cancer Prevention.2015; 16(6): 2531. CrossRef
Dual effects of human adipose tissue-derived mesenchymal stem cells in human lung adenocarcinoma A549 xenografts and colorectal adenocarcinoma HT-29 xenografts in mice
JUNG JOO RHYU, JUN-WON YUN, EUNA KWON, JEONG-HWAN CHE, BYEONG-CHEOL KANG
Oncology Reports.2015; 34(4): 1733. CrossRef
The flavonoid morin from Moraceae induces apoptosis by modulation of Bcl-2 family members and Fas receptor in HCT 116 cells
HWANG-BO HYUN, WON SUP LEE, SE-IL GO, ARULKUMAR NAGAPPAN, CHEOL PARK, MIN HO HAN, SU HYUN HONG, GONSUP KIM, GI YOUNG KIM, JAEHUN CHEONG, CHUNG HO RYU, SUNG CHUL SHIN, YUNG HYUN CHOI
International Journal of Oncology.2015; 46(6): 2670. CrossRef
Muscle weakness and myalgia as the initial presentation of serous ovarian carcinoma: a case report
Kyung-Jin Min, Yung-Taek Ouh, Hye-Ri Hong, Kyeong-A So, Jin Hwa Hong, Jae-Kwan Lee
Journal of Ovarian Research.2014;[Epub] CrossRef
Development and evaluation of the Korean version of the Gynecologic Cancer Lymphedema Questionnaire in gynecologic cancer survivors
Myong Cheol Lim, Jeong Seon Lee, Jungnam Joo, KiByung Park, Heon Jong Yoo, Sang-Soo Seo, Sokbom Kang, Seung Hyun Chung, Sang-Yoon Park
Gynecologic Oncology.2014; 133(1): 111. CrossRef
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer
Keun-Wook Lee, Yu Jung Kim, Kyung-Hun Lee, Sae-Won Han, Tae-Yong Kim, Do-Youn Oh, Seock-Ah Im, Tae-You Kim, Yung-Jue Bang, In Sil Choi, Jee Hyun Kim
Cancer Chemotherapy and Pharmacology.2014; 74(3): 447. CrossRef
Tuberculous Peritonitis Mimicking Primary Peritoneal Carcinoma
Hyeok Chan Kwon, Do Hyoung Lim, Ji Sung Choi, Suk Bin Jang, Keon Woo Park, Jae Seuk Park, Soon Il Lee
Journal of the Korean Geriatrics Society.2014; 18(1): 35. CrossRef
Novel fusion transcripts in human gastric cancer revealed by transcriptome analysis
H-P Kim, G-A Cho, S-W Han, J-Y Shin, E-G Jeong, S-H Song, W-C Lee, K-H Lee, D Bang, J-S Seo, J-Il Kim, T-Y Kim
Oncogene.2014; 33(47): 5434. CrossRef
Priorities for the primary prevention of breast cancer
Graham A. Colditz, Kari Bohlke
CA: A Cancer Journal for Clinicians.2014; 64(3): 186. CrossRef
Presymptomatic Identification of CDH1 Germline Mutation in a Healthy Korean Individual with Family History of Gastric Cancer
Hyun-Jung Choi, Chang-Seok Ki, Soon-Pal Suh, Jong-Won Kim
Annals of Laboratory Medicine.2014; 34(5): 386. CrossRef
Obesity is associated with higher risk of prostate cancer detection in a biopsy population in Korea
Juhyun Park, Sung Yong Cho, Seung Bae Lee, Hwancheol Son, Hyeon Jeong
BJU International.2014; 114(6): 891. CrossRef
Setting a Health Policy Research Agenda for Controlling Cancer Burden in Korea
Sung-In Jang, Kyoung-Hee Cho, Sun Jung Kim, Kwang-Sig Lee, Eun-Cheol Park
Cancer Research and Treatment.2014; 47(2): 149. CrossRef
Biomarkers of thyroid function and autoimmunity for predicting high-risk groups of thyroid cancer: a nested case–control study
Young Ae Cho, Sun-Young Kong, Aesun Shin, Jeonghee Lee, Eun Kyung Lee, You Jin Lee, Jeongseon Kim
BMC Cancer.2014;[Epub] CrossRef
The Use of High-Throughput Screening in Identifying Chemotherapeutic Agents for Gastric Cancer
Horst Flotow
Future Medicinal Chemistry.2014; 6(18): 2103. CrossRef
A novel oxiranylchromenone derivative, MHY336, induces apoptosis and cell cycle arrest via a p53- and p21-dependent pathway in HCT116 human colon cancer cells
SUN HWA LEE, YONG JUNG KANG, DONG HWAN KIM, BOKYUNG SUNG, JIN AH KANG, PUSOON CHUN, JEONG-HYUN YOON, HYUNG RYONG MOON, HYUNG SIK KIM, HAE YOUNG CHUNG, NAM DEUK KIM
International Journal of Oncology.2014; 44(3): 943. CrossRef
Prognostic Factors for the Selection of Patients Eligible for Second-Line Chemotherapy in Advanced Biliary Tract Cancer
Eun Joo Kang, Yoon Ji Choi, Jung Sun Kim, Kyong Hwa Park, Sang Chul Oh, Jae Hong Seo, Hong Jun Kim, Ka-won Kang, Eun Sang Yu, Sang W. Shin, Yeul H. Kim, Jun Suk Kim
Chemotherapy.2014; 60(2): 91. CrossRef
Flavonoids from Orostachys japonicus A. Berger Inhibit the Invasion of LnCaP Prostate Carcinoma Cells by Inactivating Akt and Modulating Tight Junctions
Dong Shin, Won Lee, Ji Jung, Su Hong, Cheol Park, Hye Kim, Gi-Young Kim, Hye Hwang, Gon Kim, Jin-Myung Jung, Chung Ryu, Sung Shin, Soon Hong, Yung Choi
International Journal of Molecular Sciences.2013; 14(9): 18407. CrossRef
Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010
Myong Cheol Lim, Eun-Kyeong Moon, Aesun Shin, Kyu-Won Jung, Young-Joo Won, Sang Soo Seo, Sokbom Kang, Jae-Weon Kim, Joo-Young Kim, Sang-Yoon Park
Journal of Gynecologic Oncology.2013; 24(4): 298. CrossRef
Association of Selected Medical Conditions With Breast Cancer Risk in Korea
Sun Jae Jung, Minkyo Song, Ji-Yeob Choi, Nan Song, Sue Kyung Park, Keun-Young Yoo, Daehee Kang
Journal of Preventive Medicine and Public Health.2013; 46(6): 346. CrossRef
Dosimetric evaluation of Tomotherapy and four-box field conformal radiotherapy in locally advanced rectal cancer
Mina Yu, Hong Seok Jang, Dong Min Jeon, Geum Seong Cheon, Hyo Chun Lee, Mi Joo Chung, Sung Hwan Kim, Jong Hoon Lee
Radiation Oncology Journal.2013; 31(4): 252. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Prediction of Cancer Incidence and Mortality in Korea, 2013

Cancer Res Treat. 2013;45(1):15-21. Published online March 31, 2013

DOI: https://doi.org/10.4143/crt.2013.45.1.15

XML Download

Abstract
Introduction
Materials and Methods
Results
Conclusion
Acknowledgments
NOTES
REFERENCES

Prediction of Cancer Incidence and Mortality in Korea, 2013

Fig. 1 The 10 leading types of estimated new cancer cases and deaths by sex in 2013. (A) Estimated new cases. (B) Estimated deaths.

Fig. 2 Projected age-specific incidences of major cancers during 2013 in Korea. (A) Male. (B) Female.

Fig. 3 Projected age-specific mortality rates of major cancers during 2013 in Korea. (A) Male. (B) Female.

Fig. 1

Fig. 2

Fig. 3

Prediction of Cancer Incidence and Mortality in Korea, 2013

Site	Estimated new cases			Estimated deaths
Site	Both	Male	Female	Both	Male	Female
All sites	247,732	123,610	124,122	74,179	46,610	27,569
Lip, oral cavity, and pharynx	2,897	2,142	755	1,007	739	268
Esophagus	2,273	2,089	184	1,242	1,158	84
Stomach	33,118	22,495	10,623	8,292	5,346	2,946
Colon and rectum	33,789	20,745	13,044	9,221	5,620	3,601
Liver	16,845	12,456	4,389	10,734	8,005	2,729
Gallbladder^a)	5,637	2,823	2,814	3,918	1,893	2,025
Pancreas	5,581	2,986	2,595	5,037	2,732	2,305
Larynx	1,072	1,032	40	211	200	11
Lung	23,543	16,479	7,064	16,448	11,963	4,485
Breast	17,104	67	17,037	2,207	18	2,189
Cervix uteri	3,240	-	3,240	825	-	825
Corpus uteri	2,174	-	2,174	262	-	262
Ovary	2,199	-	2,199	1,003	-	1,003
Prostate	12,180	12,180	-	1,620	1,620	-
Testis	221	221	-	19	19	-
Kidney	4,549	3,139	1,410	894	596	298
Bladder	4,043	3,255	788	1,087	780	307
Brain and CNS	1,872	999	873	1,112	608	504
Thyroid	52,485	8,512	43,973	372	104	268
Hodgkin lymphoma	267	173	94	52	30	22
Non-Hodgkin lymphoma	4,684	2,580	2,104	1,521	876	645
Multiple myeloma	1,312	689	623	965	515	450
Leukemia	2,936	1,657	1,279	1,690	977	713
Other and ill defined	13,711	6,891	6,820	4,440	2,811	1,629

Site	Crude incidence rate per 100,000			Age-standardized incidence rate per 100,000^a)
Site	Both	Male	Female	Both	Male	Female
All sites	491.0	489.8	492.2	324.2	350.4	318.4
Lip, oral cavity, and pharynx	5.7	8.5	3.0	3.9	6.0	2.0
Esophagus	4.5	8.3	0.7	2.8	5.9	0.4
Stomach	65.6	89.1	42.1	41.9	62.6	24.6
Colon and rectum	67.0	82.2	51.7	42.7	58.1	29.8
Liver	33.4	49.4	17.4	21.4	34.4	9.8
Gallbladder^b)	11.2	11.2	11.2	6.7	8.0	5.6
Pancreas	11.1	11.8	10.3	6.7	8.4	5.3
Larynx	2.1	4.1	0.2	1.3	2.9	0.1
Lung	46.7	65.3	28.0	28.2	46.1	15.0
Breast	33.9	0.3	67.6	23.1	0.2	45.8
Cervix uteri	6.4	-	12.9	4.3	-	8.4
Corpus uteri	4.3	-	8.6	2.9	-	5.7
Ovary	4.4	-	8.7	3.0	-	6.0
Prostate	24.1	48.3	-	15.0	34.5	-
Testis	0.4	0.9	-	0.5	0.9	-
Kidney	9.0	12.4	5.6	6.1	8.9	3.6
Bladder	8.0	12.9	3.1	4.8	9.1	1.6
Brain and CNS	3.7	4.0	3.5	3.1	3.5	2.7
Thyroid	104.0	33.7	174.4	73.7	24.0	124.1
Hodgkin lymphoma	0.5	0.7	0.4	0.5	0.6	0.3
Non-Hodgkin lymphoma	9.3	10.2	8.3	6.6	7.8	5.6
Multiple myeloma	2.6	2.7	2.5	1.6	1.9	1.4
Leukemia	5.8	6.6	5.1	5.2	6.1	4.4
Other and ill defined	27.2	27.3	27.0	18.3	20.7	16.4

Rank	Age group (yr)
Rank	0-14	15-34	35-64	≥65
Male
1	Leukemia	Thyroid	Stomach	Lung
	(5.1)	(14.6)	(99.9)	(478.9)
2	Brain and CNS	Leukemia	Colon and rectum	Stomach
	(2.6)	(3.3)	(90.9)	(445.5)
3	Non-Hodgkin lymphoma	Colon and rectum	Liver	Colon and rectum
	(2.0)	(3.0)	(64.5)	(414.0)
4	Kidney	Non-Hodgkin lymphoma	Thyroid	Prostate
	(0.6)	(3.0)	(57.4)	(374.0)
5	Testis	Stomach	Lung	Liver
	(0.4)	(2.3)	(41.7)	(202.9)
Female
1	Leukemia	Thyroid	Thyroid	Colon and rectum
	(4.0)	(79.3)	(307.8)	(204.9)
2	Brain and CNS	Breast	Breast	Stomach
	(2.0)	(11.4)	(123.8)	(157.0)
3	Non-Hodgkin lymphoma	Cervix uteri	Colon and rectum	Lung
	(1.0)	(5.2)	(50.8)	(131.4)
4	Ovary	Stomach	Stomach	Thyroid
	(0.8)	(4.2)	(43.2)	(108.0)
5	Thyroid	Ovary	Lung	Liver
	(0.6)	(2.8)	(21.7)	(78.2)

Site	Crude mortality rate per 100,000			Age-standardized mortality rate per 100,000^a)
Site	Both	Male	Female	Both	Male	Female
All sites	147.0	184.7	109.3	87.7	131.8	56.3
Lip, oral cavity, and pharynx	2.0	2.9	1.1	1.2	2.0	0.6
Esophagus	2.5	4.6	0.3	1.5	3.2	0.1
Stomach	16.4	21.2	11.7	9.6	15.1	5.7
Colon and rectum	18.3	22.3	14.3	10.7	16.0	7.0
Liver	21.3	31.7	10.8	13.3	22.3	5.6
Gallbladder^b)	7.8	7.5	8.0	4.4	5.4	3.7
Pancreas	10.0	10.8	9.1	5.9	7.7	4.5
Larynx	0.4	0.8	0.0	0.2	0.6	0.0
Lung	32.6	47.4	17.8	18.9	33.4	8.6
Breast	4.4	0.1	8.7	2.9	0.1	5.5
Cervix uteri	1.6	-	3.3	1.0	-	1.8
Corpus uteri	0.5	-	1.0	0.3	-	0.6
Ovary	2.0	-	4.0	1.2	-	2.3
Prostate	3.2	6.4	-	1.7	4.8	-
Testis	0.0	0.1	-	0.0	0.1	-
Kidney	1.8	2.4	1.2	1.1	1.7	0.6
Bladder	2.2	3.1	1.2	1.2	2.3	0.5
Brain and CNS	2.2	2.4	2.0	1.6	1.9	1.3
Thyroid	0.7	0.4	1.1	0.4	0.3	0.5
Hodgkin lymphoma	0.1	0.1	0.1	0.1	0.1	0.1
Non-Hodgkin lymphoma	3.0	3.5	2.6	1.8	2.5	1.3
Multiple myeloma	1.9	2.0	1.8	1.2	1.4	1.0
Leukemia	3.4	3.9	2.8	2.3	3.0	1.8
Other and ill defined	8.8	11.1	6.5	5.3	8.1	3.3

Table 1 Estimated new cancer cases and deaths by sex during 2013 in Korea

CNS, central nervous system. ^a)Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 2 Estimated crude and age-standardized cancer incidences by sex during 2013 in Korea

CNS, central nervous system. ^a)Age adjusted to the world standard population, ^b)Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 3 Estimated cancer incidence by age group and sex during 2013 in Korea

CNS, central nervous system.

Table 4 Estimated crude and age-standardized cancer mortality rates by sex during 2013 in Korea

CNS, central nervous system. ^a)Age adjusted to the world standard population, ^b)Includes the gallbladder and other/unspecified parts of the biliary tract.